Editas Medicine
EDIT
312 hedge funds and large institutions have $2.23B invested in Editas Medicine in 2021 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 117 increasing their positions, 71 reducing their positions, and 60 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 71
36% more call options, than puts
Call options by funds: $97.1M | Put options by funds: $71.2M
7% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 60
0% more funds holding
Funds holding: 311 → 312 (+1)
6.03% less ownership
Funds ownership: 85.02% → 78.99% (-6%)
40% less capital invested
Capital invested by funds: $3.72B → $2.23B (-$1.49B)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$41.8M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$30.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.8M |
| 4 |
Renaissance Technologies
New York
|
+$26M |
| 5 |
BlackRock
New York
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$78.3M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$61.4M |
| 3 |
Chevy Chase Trust
Bethesda,
Maryland
|
-$58.3M |
| 4 |
D.E. Shaw & Co
New York
|
-$46M |
| 5 |
DM
Deerfield Management
New York
|
-$37.8M |
EDIT Hedge Fund Activity: Q1 2021 in Review
312 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2021, worth a combined $2.23B — down 40% from $3.72B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new EDIT positions and 60 closed out — a net gain of 4 holders — while 117 added to existing stakes and 71 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $41.8M. The largest seller was ARK Investment Management, cutting an estimated $78.3M.
- 312 institutional investors held Editas Medicine (EDIT) as of Q1 2021, up from 311 in Q4 2020.
- Funds reported $2.23B of Editas Medicine stock for Q1 2021, down 40% quarter-over-quarter.
- 64 funds opened new Editas Medicine positions in Q1 2021 and 60 closed out, a net change of +4 holders.
- The largest Editas Medicine buyer in Q1 2021 was Two Sigma Investments, an estimated $41.8M added.
- The largest Editas Medicine seller in Q1 2021 was ARK Investment Management, an estimated $78.3M sold.
Based on aggregated 13F filings for Q1 2021.